Experience in Core LIMS, Exemplar LIMS or Clarity LIMS with in Lab experience. Preferably with experience in the Life Sciences/Biotechnology industries. RollFrom Indeed – Wed, 28 Sep 2016 14:05:53 GMT – View all La Jolla jobs
1-3 years’ experience as a CRA in the biotechnology or pharmaceutical industry. The CRA will report to the Assistant Director of Clinical and Regulatory…
From Real Staffing – Wed, 28 Sep 2016 12:41:47 GMT – View all San Diego jobs
Dermata Therapeutics, LLC Announces Positive Top-line Results from their Phase 1 Pharmacokinetic Study of DMT210 in Acne Rosacea Patients
SAN DIEGO, Sept. 28, 2016 /PRNewswire/ — Dermata Therapeutics, LLC, a biotechnology company focused on developing innovative medical dermatology products for dermatologists and their patients, today announces positive findings from their 28-day Phase 1 Pharmacokinetic Study in Acne Rosacea patients with their lead compound, DMT210. The results from the Phase 1 study show that DMT210 has minimal systemic exposure, an acceptable safety profile and appears well tolerated by patients, with most reported local skin reactions as mild.
Dermata also collected efficacy data, producing meaningful results, by measuring the four main clinical endpoints for rosacea: reduction in lesion counts, investigator global assessment in rosacea, clinician’s assessment of erythema, and patient’s severity assessment of erythema. These results are consistent with the findings of their non-clinical data, which indicated DMT210 may be effective to treat both the erythema and inflammation (papules and pustules) associated with rosacea.
“The safety results are supported with the findings from our pre-clinical data that DMT210 has a favorable safety profile, which remains extremely important to patients and dermatologists for dermal products,” states Gerald Proehl, President and CEO of Dermata. “We are also very excited to see that DMT210 reduced erythema and lesion counts in only a 28-day study, giving us further confidence that we will see even greater reductions in our 90-day study.”
With the completion of this study, Dermata plans to move into two Phase 2 studies in Acne Rosacea and Atopic Dermatitis, both expected to start later this year.
About Dermata: Dermata is a development-stage biotechnology company focused on making major advancements in the treatment of serious diseases treated by dermatologists. Dermata has a team of experienced individuals who are currently focused on progressing four programs for the treatment of acne rosacea, acne vulgaris, atopic dermatitis and ocular rosacea. To learn more about Dermata and its pipeline of treatments, please visit www.dermatarx.com.
President and CEO
SOURCE Dermata Therapeutics, LLC
SAN DIEGO, Sept. 28, 2016 /PRNewswire/ — GenomeDx Biosciences and SouthGenetics Inc. today announced that they have signed a strategic agreement to bring GenomeDx’s Decipher® Prostate Cancer Classifier Tests to several Latin American countries, including Mexico, Argentina, Colombia and Uruguay. SouthGenetics has established itself as a leader in the introduction of new diagnostic techniques to the Latin America market.
Under the terms of the agreement, SouthGenetics will have exclusive distribution rights to market and sell GenomeDx’s Decipher Biopsy and Decipher Post-Op genomic tests for men diagnosed with localized prostate cancer in their markets. The tests are performed either at the time of biopsy or following prostate removal surgery and evaluate RNA expression-based biomarkers to predict the risk of high-grade disease, metastasis and cancer-specific death. The tests will be offered through SouthGenetics’ commercial channel, with the testing performed by GenomeDx at its centralized, CAP-accredited, CLIA-certified laboratory in San Diego, California. GenomeDx will rely upon the expertise of SouthGenetics to obtain regulatory and reimbursement approvals.
“More than 130,000 men in Central and South America are diagnosed with prostate cancer each year. We believe our Decipher tests will allow physicians throughout Latin America to more accurately assess tumor aggressiveness and stratify prostate cancer patients into more accurate risk groups, thereby helping to guide optimal treatment and care for their patients,” said Doug Dolginow, M.D., chief executive officer of GenomeDx. “We are excited to expand our global footprint and look forward to collaborating with SouthGenetics to provide prostate cancer patients in Latin America with access to our genomic tests and the valuable insights they can offer.”
“SouthGenetics strives to provide physicians and patients rapid access to highly complex genomic solutions,” said Washington Rodriguez, chief executive officer of SouthGenetics. “As one of the premier providers of genomic solutions for urologic cancer management, we are excited to partner with GenomeDx, allowing us to expand our offerings in urologic oncology and enabling better personalization of therapy for patients.”
About Decipher® Prostate Cancer Classifier Tests
Our Decipher Prostate Cancer Classifier tests currently include Decipher Biopsy and Decipher Post-Op. These commercially available genomic tests provide an assessment of tumor aggressiveness based on the patient’s unique genomic profile. Decipher Biopsy is indicated for men with localized prostate cancer after biopsy diagnosis and Decipher Post-Op is indicated for men after prostate removal surgery. The Decipher tests are used by physicians to stratify patients into more accurate risk groups to better determine which patients will likely benefit from additional treatment and which will not, thereby enabling improved decision-making and helping low-risk patients avoid unnecessary treatments that have serious adverse side effects and result in unnecessary costs to the healthcare system. Studies of thousands of patients from leading cancer centers, published in multiple peer-reviewed journals, demonstrate that the Decipher tests can more accurately predict disease aggressiveness than traditional clinical measures, such as PSA and Gleason score. Decipher Post-Op is covered by Medicare and by a number of private payors and preferred provider organizations representing, together with Medicare, about 70% of the approximately 66 million adult men in the United States age 40 or older who are at increased risk of being diagnosed with prostate cancer.
About Decipher GRID®
Our Decipher Genomics Resource Information Database (Decipher GRID) is a genomic expression database that provides a foundation for open and interactive research collaboration and knowledge creation. Decipher GRID is a rapidly growing database that contains genomic profiles of thousands of patient tumors, and constitutes what we believe to be the world’s largest shared, clinically-annotated genomic expression database in urologic cancer as well as one of the world’s largest global RNA expression databases utilizing cloud-based analytics. We believe Decipher GRID gives rise to new opportunities for information technology-enabled genomic solutions and enables us to more rapidly discover, develop, commercialize and drive the adoption of our existing and new genomic tests. Through Decipher GRID, GenomeDx is building a suite of genomic tests in urologic cancer that we believe will allow us to achieve our goals of reducing costs to the healthcare system and improving patient lives, from screening through late-stage therapy.
About GenomeDx Biosciences
GenomeDx Biosciences uses the power of collaborative genomics to transform the management and treatment of cancer patients. GenomeDx has built Decipher GRID, a large genomics database in urologic cancer that provides a foundation for open and interactive research collaboration and knowledge creation. Using Decipher GRID to analyze vast amounts of genomic data, GenomeDx develops and commercializes proprietary clinical tests that are intended to provide more accurate and useful diagnostic information than both traditional diagnostic tools and existing genomic tests. GenomeDx’s Decipher Biopsy and Decipher Post-Op are commercially available prostate cancer genomic tests that provide an assessment of tumor aggressiveness based on a patient’s unique genomic profile. GenomeDx is headquartered in Vancouver, British Columbia and has offices in San Diego, California.
Learn more at www.GenomeDx.com
SOURCE GenomeDx Biosciences
Ionis Pharmaceuticals’ CEO, Dr. Stanley Crooke, Receives Lifetime Achievement Award from the Oligonucleotide Therapeutics Society
CARLSBAD, Calif., Sept. 28, 2016 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that Stanley T. Crooke, Ph.D., M.D., founder, CEO and chairman of the board of directors of Ionis Pharmaceuticals, Inc., has been awarded the Lifetime Achievement Award from the Oligonucleotide Therapeutics Society, OTS. The OTS Lifetime Achievement Award recognizes Dr. Crooke’s lasting commitment to the field of oligonucleotide therapeutics through outstanding contributions to education, research, and therapeutic application. Dr. Crooke’s accomplishments will be recognized at the 2016 OTS Annual Meeting in Montreal, Quebec, Canada and he will give a plenary lecture at the meeting on Wednesday, September 28, 2016 from 9:30 a.m. to 10:30 a.m. EDT.
“The OTS Lifetime Achievement Award is reserved for a distinguished individual who has made remarkable contributions to the advancement of the field of oligonucleotide sciences. As a renowned leader in the field, Dr. Crooke is exceptionally well-deserving of this award,” said Dr. Masad Damha, former president of the OTS, current chairman of the OTS awards committee and professor of chemistry at McGill University in Montreal, Canada. “Dr. Crooke has revolutionized the field of oligonucleotide therapeutics through his pioneering work in the creation of antisense technology – a novel, disruptive drug discovery and development platform. We have already seen the value of antisense technology materialize into therapeutic benefit today and we look forward to seeing the important impact antisense medicines will have on healthcare in the future.”
Dr. Crooke has demonstrated, throughout his career, his commitment to discovering and developing novel medicines for patients with high unmet medical need. In 1989, Dr. Crooke founded Ionis Pharmaceuticals, where he has led the creation of a novel drug discovery platform, antisense technology. Dr. Crooke oversaw the discovery and development of the first two RNA-targeted drugs to achieve regulatory approval and commercialization. Under Dr. Crooke’s leadership, Ionis has grown and advanced its pipeline to over three dozen drugs in development, with three additional Phase 3 drugs approaching commercialization.
“I am deeply grateful to be recognized by my peers at the Oligonucleotide Therapeutics Society with this esteemed award,” said Dr. Crooke. “I am keenly interested in exploiting oligonucleotide sciences to tap into its immense therapeutic potential. At Ionis, we are focused on innovation and we persistently invest in core research to continue the advancement of our antisense technology. These investments are translating into real value across our pipeline today and we look forward to delivering transformative medicines to patients in need.”
ABOUT STANLEY T. CROOKE, M.D., PH.D.
Dr. Crooke is recognized as one the world’s foremost experts on antisense technology. In addition to his responsibilities as the CEO and chairman of the board of directors at Ionis, he leads an active research lab focused on advancing antisense drug technology through the elucidation of its underlying molecular mechanisms. His publications include over 450 scientific papers and he has edited 21 books.
Dr. Crooke started his industry career at Bristol Laboratories where he helped to establish the anticancer drug discovery and development program and played a key role in bringing to market a significant number of anticancer drugs. Later, at SmithKline, he oversaw worldwide R&D, coordinated all research activities, including instruments and diagnostics, and was involved in commercializing numerous new drugs in broad therapeutic areas. Dr. Crooke received his M.D. and Ph.D. degrees and house staff training at Baylor College of Medicine and has been an active scientist throughout his career.
Dr. Crooke has also supported the creation and growth of a number of companies based on Ionis’ technology, including Akcea, Regulus, Ibis and others. He has served as a board member of 22 biotechnology and scientific companies and is currently a member of the board of directors of the Biotechnology Industry Organization (BIO). Dr. Crooke has been the recipient of numerous awards. Most recently, Dr. Crooke was recognized with the E.B. Hershberg Award for important discoveries in medicinally active substances from the American Chemical Society. Dr. Crooke also recently accepted the SCRIP Lifetime Achievement Award, which recognizes his dedication to advancing science and medicine as a physician, a scientist, a leader and as a successful entrepreneur. Nature Biotechnology named him as one of the most influential individuals in biotechnology. He was awarded the Director of the Year Award from the Corporate Directors Forum; the Distinguished Scientist Award from the American Chemical Society (San Diego Chapter); the Helix Award, for the most important innovation in biotechnology by BIO, Stony Brook University and the Center for Biotechnology; and the Ernst and Young Entrepreneur of the Year Award. Dr. Crooke was also recognized as a Distinguished Alumnus at both Baylor College of Medicine and Butler University.
ABOUT IONIS PHARMACEUTICALS, INC.
Ionis is the leading company in RNA-targeted drug discovery and development focused on developing drugs for patients who have the highest unmet medical needs, such as those patients with severe and rare diseases. Using its proprietary antisense technology, Ionis has created a large pipeline of first-in-class or best-in-class drugs, with over a dozen drugs in mid- to late-stage development. Drugs currently in Phase 3 development include volanesorsen, a drug Ionis is developing and plans to commercialize through its wholly owned subsidiary, Akcea Therapeutics, to treat patients with either familial chylomicronemia syndrome or familial partial lipodystrophy; IONIS-TTRRx, a drug Ionis is developing with GSK to treat patients with all forms of TTR amyloidosis; and nusinersen, a drug Ionis is developing with Biogen to treat infants and children with spinal muscular atrophy. Ionis’ patents provide strong and extensive protection for its drugs and technology. Additional information about Ionis is available at www.ionispharma.com.
IONIS’ FORWARD-LOOKING STATEMENT
This press release includes forward-looking statements regarding the therapeutic and commercial potential of Ionis’ technologies and products in development, including nusinersen, IONIS-TTRRx and volanesorsen. Any statement describing Ionis’ goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. Ionis’ forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Ionis’ forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Ionis. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Ionis’ programs are described in additional detail in Ionis’ annual report on Form 10-K for the year ended December 31, 2015, and its most recent quarterly report on Form 10-Q, which are on file with the SEC. Copies of these and other documents are available from the Company.
In this press release, unless the context requires otherwise, “Ionis,” “Company,” “we,” “our,” and “us” refers to Ionis Pharmaceuticals and its subsidiaries.
Ionis Pharmaceuticals™ is a trademark of Ionis Pharmaceuticals, Inc. Akcea Therapeutics™ is a trademark of Ionis Pharmaceuticals, Inc.
SOURCE Ionis Pharmaceuticals, Inc.
Growing biotechnology company seeks enthusiastic individual to assist in developing an enabling and disruptive gene expression technology….From BioPhase Solutions – Wed, 28 Sep 2016 08:45:53 GMT – View all San Diego jobs
Biology background or experience in biotech is a plus. Build out data access layer components using T-SQL stored procedures, Entity Framework and SQL server…. $66 an hour
From International Programming & Systems Inc. – Wed, 28 Sep 2016 05:11:31 GMT – View all San Diego jobs
Biology background or experience in biotech is a plus. Build out data access layer components using T-SQL stored procedures, Entity Framework and SQL server…. $58 an hour
From International Programming & Systems Inc. – Wed, 28 Sep 2016 05:11:30 GMT – View all San Diego jobs
Executive Account Specialist – Health Systems Management – San Diego, CA Allergan plc (NYSE: AGN) is a bold, global pharmaceutical company and a leader in aFrom Allergan – Wed, 28 Sep 2016 04:24:55 GMT – View all San Diego jobs
Is a premier pharmaceutical chemistry development and manufacturing organization supporting the pharmaceutical and biotechnology industries….From Pharmatek – Wed, 28 Sep 2016 03:58:45 GMT – View all San Diego jobs